Celltrion’s Rituximab Biosimilar Enjoys A Market Share Of More Than A Third In Europe

 
• By Dean Rudge
  
PumpkinPie
Celltrion's slice of the European rituximab market is around 35% • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products